{"transactions":[{"id":4635262,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-03T00:15:31.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":1352,"price":12.29,"value":16616.08,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The options were issued to the Reporting Person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Plan in lieu of Board fees."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on September 30, 2026, and are 100% vested."}],"balance_after":1352,"derivative":{"exercise_price":15.33,"expiration_date":"2036-09-30","underlying":"Common Stock","underlying_shares":1352},"source":{"system":"sec-edgar","filing":"0001677036-26-000009","document":"form4-10022026_041018.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167703626000009/form4-10022026_041018.xml","form_type":"4"}},{"id":698928,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:09.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":108916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":108916,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Common Stock","underlying_shares":108916},"source":{"system":"sec-edgar","filing":"0001193125-26-330505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330505/ownership.xml","form_type":"4"}},{"id":698927,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:09.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Class A Common Stock","underlying_shares":108916},"source":{"system":"sec-edgar","filing":"0001193125-26-330505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330505/ownership.xml","form_type":"4"}},{"id":698926,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:09.000Z","date":"2026-07-30","kind":"grant","planned":false,"acquired":true,"shares":108916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":108916,"derivative":{"exercise_price":16,"expiration_date":"2036-07-29","underlying":"Class A Common Stock","underlying_shares":108916},"source":{"system":"sec-edgar","filing":"0001193125-26-330505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330505/ownership.xml","form_type":"4"}},{"id":698925,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:09.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":1186278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":1186278,"derivative":{"exercise_price":8.15,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":1186278},"source":{"system":"sec-edgar","filing":"0001193125-26-330505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330505/ownership.xml","form_type":"4"}},{"id":698924,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:09.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1186278,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 1, 2026 and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":8.15,"expiration_date":"2036-06-23","underlying":"Class A Common Stock","underlying_shares":1186278},"source":{"system":"sec-edgar","filing":"0001193125-26-330505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330505/ownership.xml","form_type":"4"}},{"id":698923,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:09.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":74128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":74128,"derivative":{"exercise_price":9.5,"expiration_date":"2035-03-06","underlying":"Common Stock","underlying_shares":74128},"source":{"system":"sec-edgar","filing":"0001193125-26-330505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330505/ownership.xml","form_type":"4"}},{"id":698922,"issuer":{"id":4910,"kind":"organization","name":"Apnimed, Inc."},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-03T20:01:09.000Z","date":"2026-08-03","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":74128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after March 6, 2025, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":0,"derivative":{"exercise_price":9.5,"expiration_date":"2035-03-06","underlying":"Class A Common Stock","underlying_shares":74128},"source":{"system":"sec-edgar","filing":"0001193125-26-330505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1745648/000119312526330505/ownership.xml","form_type":"4"}},{"id":717300,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:05:28.000Z","date":"2026-06-30","kind":"grant","planned":false,"acquired":true,"shares":1105,"price":15.04,"value":16619.2,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on June 30, 2026, and are 100% vested."}],"balance_after":1105,"derivative":{"exercise_price":18.48,"expiration_date":"2036-06-30","underlying":"Common Stock","underlying_shares":1105},"source":{"system":"sec-edgar","filing":"0001677036-26-000006","document":"form4-07022026_040719.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167703626000006/form4-07022026_040719.xml","form_type":"4"}},{"id":749268,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-04T20:10:15.000Z","date":"2026-06-02","kind":"grant","planned":false,"acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests 100% on the first anniversary of the date of grant, subject to the director's continued service on such vesting date."}],"balance_after":20100,"derivative":{"exercise_price":13.96,"expiration_date":"2036-06-02","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001677036-26-000004","document":"form4-06042026_040609.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167703626000004/form4-06042026_040609.xml","form_type":"4"}},{"id":822569,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-04-01T20:05:19.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":1370,"price":12.13,"value":16618.1,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on March 31, 2026, and are 100% vested."}],"balance_after":1370,"derivative":{"exercise_price":14.93,"expiration_date":"2036-03-31","underlying":"Common Stock","underlying_shares":1370},"source":{"system":"sec-edgar","filing":"0001677036-26-000002","document":"form4-04012026_040408.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167703626000002/form4-04012026_040408.xml","form_type":"4"}},{"id":950296,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-05T21:05:55.000Z","date":"2025-12-31","kind":"grant","planned":false,"acquired":true,"shares":848,"price":14.74,"value":12499.52,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options were granted on December 31, 2025, and are 100% vested."}],"balance_after":848,"derivative":{"exercise_price":18.16,"expiration_date":"2035-12-31","underlying":"Common Stock","underlying_shares":848},"source":{"system":"sec-edgar","filing":"0001470831-26-000007","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000147083126000007/form4.xml","form_type":"4"}},{"id":1026568,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-02T20:23:28.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":40200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in three substantially equal installments on the first, second and third anniversary of the date of grant, subject to the Eligible Director's continued service on each such vesting date."}],"balance_after":40200,"derivative":{"exercise_price":12.96,"expiration_date":"2035-10-01","underlying":"Common Stock","underlying_shares":40200},"source":{"system":"sec-edgar","filing":"0001677036-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000167703625000004/primary_doc.xml","form_type":"4"}},{"id":1346827,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2024-12-03T00:17:15.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the \"Retention RSUs\"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time."},{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the \"Retention RSUs\"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The vesting of the Retention RSUs was not accelerated prior to the Effective Time. The Merger Consideration paid in respect of the Retention RSUs is subject to vesting (and payment upon such vesting) upon the earliest to occur of 10/25/2025 (subject to the employee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through such date), or the date the executive officer incurs an \"involuntary termination\" (as defined in such officer's respective employment agreement with the Issuer)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the \"Retention RSUs\"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The vesting of the Retention RSUs was not accelerated prior to the Effective Time. The Merger Consideration paid in respect of the Retention RSUs is subject to vesting (and payment upon such vesting) upon the earliest to occur of 10/25/2025 (subject to the employee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through such date), or the date the executive officer incurs an \"involuntary termination\" (as defined in such officer's respective employment agreement with the Issuer)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each restricted stock unit award granted on 10/25/2024 to certain of the Issuer's employees, including executive officers (the \"Retention RSUs\"), whether vested or unvested, became the right to receive an amount in cash, without interest, equal to the product of (i) the total number of Shares issuable in settlement of such Retention RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding of taxes, payable in accordance with, and subject to satisfaction of, the remaining vesting schedule of the Retention RSUs as in effect immediately prior to the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The vesting of the Retention RSUs was not accelerated prior to the Effective Time. The Merger Consideration paid in respect of the Retention RSUs is subject to vesting (and payment upon such vesting) upon the earliest to occur of 10/25/2025 (subject to the employee's Continuous Service (as defined in the 2021 Equity Incentive Plan) through such date), or the date the executive officer incurs an \"involuntary termination\" (as defined in such officer's respective employment agreement with the Issuer)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-24-028021","document":"form4-12032024_121211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000141588924028021/form4-12032024_121211.xml","form_type":"4"}},{"id":1346826,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-03T00:17:15.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":332134,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":19.32,"expiration_date":"2034-02-07","underlying":"Common Stock","underlying_shares":332134},"source":{"system":"sec-edgar","filing":"0001415889-24-028021","document":"form4-12032024_121211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000141588924028021/form4-12032024_121211.xml","form_type":"4"}},{"id":1346825,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-03T00:17:15.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":325850,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":4.35,"expiration_date":"2033-02-08","underlying":"Common Stock","underlying_shares":325850},"source":{"system":"sec-edgar","filing":"0001415889-24-028021","document":"form4-12032024_121211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000141588924028021/form4-12032024_121211.xml","form_type":"4"}},{"id":1346824,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-03T00:17:15.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":192783,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":4.2,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":192783},"source":{"system":"sec-edgar","filing":"0001415889-24-028021","document":"form4-12032024_121211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000141588924028021/form4-12032024_121211.xml","form_type":"4"}},{"id":1346823,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-12-03T00:17:15.000Z","date":"2024-12-02","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":255377,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and automatically converted into the right to receive cash, without interest, in an amount equal to the product of (i) the total number of Shares subject to such option as of immediately prior to the Effective Time multiplied by (ii) the excess of (x) $60.00 per Share over (y) the exercise price payable per Share under such option, which amount will be subject to any withholding taxes."}],"balance_after":0,"derivative":{"exercise_price":3.1232,"expiration_date":"2030-10-26","underlying":"Common Stock","underlying_shares":255377},"source":{"system":"sec-edgar","filing":"0001415889-24-028021","document":"form4-12032024_121211.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000141588924028021/form4-12032024_121211.xml","form_type":"4"}},{"id":1346822,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-12-03T00:17:15.000Z","date":"2024-12-02","kind":"other","planned":false,"acquired":false,"shares":363740,"price":60,"value":21824400.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of 10/14/2024, by and among Longboard Pharmaceuticals, Inc. (the \"Issuer\"), H. Lundbeck A/S (\"Parent\"), Lundbeck LLC (\"Payor\"), and Langkawi Corporation (\"Purchaser\"), on 12/02/2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and an indirect wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, the Shares were tendered at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive $60.00 per Share, in cash, without interest, subject to any applicable withholding of taxes (the \"Merger Consideration\"). At the effective time of the Merger (being such date and at such time as the certificate of merger in respect of the Merger was duly filed with the Secretary of State of the State of Delaware in accordance with the DGCL) (the \"Effective Time\"), each issued and outstanding Share was cancelled in exchange for the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-24-028021","document":"form4-12032024_121211.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000141588924028021/form4-12032024_121211.xml","form_type":"4"}},{"id":1366159,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-14T01:48:14.000Z","date":"2024-11-13","kind":"exercise","planned":false,"acquired":false,"shares":12808,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a cash exercise of vested stock options without a subsequent sale of the underlying shares of common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares subject to the stock option vested and became exercisable in 24 equal monthly installments commencing November 27, 2022."}],"balance_after":255377,"derivative":{"exercise_price":3.1232,"expiration_date":"2030-10-26","underlying":"Common Stock","underlying_shares":12808},"source":{"system":"sec-edgar","filing":"0000950170-24-126650","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000095017024126650/ownership.xml","form_type":"4"}},{"id":1366158,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-11-14T01:48:14.000Z","date":"2024-11-13","kind":"gift","planned":false,"acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares of common stock gifted to a donor-advised trust."}],"balance_after":363740,"source":{"system":"sec-edgar","filing":"0000950170-24-126650","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000095017024126650/ownership.xml","form_type":"4"}},{"id":1366157,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-11-14T01:48:14.000Z","date":"2024-11-13","kind":"exercise","planned":false,"acquired":true,"shares":12808,"price":3.1232,"value":40001.9456,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a cash exercise of vested stock options without a subsequent sale of the underlying shares of common stock."}],"balance_after":443740,"source":{"system":"sec-edgar","filing":"0000950170-24-126650","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000095017024126650/ownership.xml","form_type":"4"}},{"id":1379877,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Retention Restricted Stock Units","published_at":"2024-10-29T20:38:30.000Z","date":"2024-10-25","kind":"grant","planned":false,"acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The retention restricted stock units (\"Retention RSUs\") vest in full on the earlier of October 25, 2025, or the date of the Reporting Person's Involuntary Termination (as defined in the Reporting Person's employment agreement) (such earlier date, the \"Vesting Date\"). The shares underlying the Retention RSUs will be issued upon vesting and release of the Retention RSUs. If the acquisition of the Issuer pursuant to the Agreement and Plan of Merger attached as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the SEC on October 15, 2024 (the \"Merger Agreement\") is completed prior to the Vesting Date, then, as of and following the Effective Time (as defined in the Merger Agreement), the Retention RSUs shall be settled via payment of an amount in cash, without interest, equal to the product of the Merger Consideration (as defined in the Merger Agreement) multiplied by the number of Retention RSUs, with such amount payable to the Reporting Person on the Vesting Date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The retention restricted stock units (\"Retention RSUs\") vest in full on the earlier of October 25, 2025, or the date of the Reporting Person's Involuntary Termination (as defined in the Reporting Person's employment agreement) (such earlier date, the \"Vesting Date\"). The shares underlying the Retention RSUs will be issued upon vesting and release of the Retention RSUs. If the acquisition of the Issuer pursuant to the Agreement and Plan of Merger attached as Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the SEC on October 15, 2024 (the \"Merger Agreement\") is completed prior to the Vesting Date, then, as of and following the Effective Time (as defined in the Merger Agreement), the Retention RSUs shall be settled via payment of an amount in cash, without interest, equal to the product of the Merger Consideration (as defined in the Merger Agreement) multiplied by the number of Retention RSUs, with such amount payable to the Reporting Person on the Vesting Date."}],"balance_after":22000,"derivative":{"exercise_price":0,"underlying":"Voting Common Stock","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0000950170-24-118308","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000095017024118308/ownership.xml","form_type":"4"}},{"id":1434469,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-13T22:03:42.000Z","date":"2024-08-12","kind":"exercise","planned":false,"acquired":false,"shares":2217,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023."}],"balance_after":192783,"derivative":{"exercise_price":4.2,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":2217},"source":{"system":"sec-edgar","filing":"0000950170-24-096499","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000095017024096499/ownership.xml","form_type":"4"}},{"id":1434468,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-13T22:03:42.000Z","date":"2024-08-12","kind":"exercise","planned":false,"acquired":false,"shares":80265,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in 24 equal monthly installments commencing November 27, 2022."}],"balance_after":268185,"derivative":{"exercise_price":3.1232,"expiration_date":"2030-10-26","underlying":"Common Stock","underlying_shares":80265},"source":{"system":"sec-edgar","filing":"0000950170-24-096499","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000095017024096499/ownership.xml","form_type":"4"}},{"id":1434467,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-08-13T22:03:42.000Z","date":"2024-08-12","kind":"exercise","planned":false,"acquired":true,"shares":2217,"price":4.2,"value":9311.4,"ownership":{"direct":true},"balance_after":430932,"source":{"system":"sec-edgar","filing":"0000950170-24-096499","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000095017024096499/ownership.xml","form_type":"4"}},{"id":1434466,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Common Stock","published_at":"2024-08-13T22:03:42.000Z","date":"2024-08-12","kind":"exercise","planned":false,"acquired":true,"shares":80265,"price":3.1232,"value":250683.648,"ownership":{"direct":true},"balance_after":428715,"source":{"system":"sec-edgar","filing":"0000950170-24-096499","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000095017024096499/ownership.xml","form_type":"4"}},{"id":1651165,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-09T21:06:55.000Z","date":"2024-02-08","kind":"grant","planned":false,"acquired":true,"shares":332134,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 8, 2024."}],"balance_after":332134,"derivative":{"exercise_price":19.32,"expiration_date":"2034-02-07","underlying":"Voting common stock","underlying_shares":332134},"source":{"system":"sec-edgar","filing":"0001209191-24-003025","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000120919124003025/doc4.xml","form_type":"4"}},{"id":2022152,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-10T21:27:01.000Z","date":"2023-02-09","kind":"grant","acquired":true,"shares":325850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2023."}],"balance_after":325850,"derivative":{"exercise_price":4.35,"expiration_date":"2033-02-08","underlying":"Voting common stock","underlying_shares":325850},"source":{"system":"sec-edgar","filing":"0001209191-23-008384","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000120919123008384/doc4.xml","form_type":"4"}},{"id":2400893,"issuer":{"id":85536,"kind":"organization","name":"Longboard Pharmaceuticals, Inc.","symbol":"LBPH"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-11T21:48:10.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":195000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the stock option vest and become exercisable in 48 equal monthly installments commencing March 9, 2022."}],"balance_after":195000,"derivative":{"exercise_price":4.2,"expiration_date":"2032-02-08","underlying":"Voting common stock","underlying_shares":195000},"source":{"system":"sec-edgar","filing":"0001209191-22-008911","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1677036/000120919122008911/doc4.xml","form_type":"4"}},{"id":3234178,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-03T18:10:08.000Z","date":"2020-03-01","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over four years, with 25% of the shares subject to the option vesting on March 1, 2021, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":70000,"derivative":{"exercise_price":44.6,"expiration_date":"2027-03-01","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-20-015576","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120015576/doc4.xml","form_type":"4"}},{"id":3271587,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-14T19:40:17.000Z","date":"2020-02-13","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":128000,"derivative":{"exercise_price":35.6,"expiration_date":"2025-01-19","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001209191-20-009834","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120009834/doc4.xml","form_type":"4"}},{"id":3271586,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-02-14T19:40:17.000Z","date":"2020-02-13","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four years, with 25% of the shares subject to the option vesting on June 15, 2017, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":77500,"derivative":{"exercise_price":19.4,"expiration_date":"2023-06-15","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001209191-20-009834","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120009834/doc4.xml","form_type":"4"}},{"id":3271585,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Common Stock","published_at":"2020-02-14T19:40:17.000Z","date":"2020-02-13","kind":"sale","acquired":false,"shares":4500,"price":55,"value":247500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan established by the reporting person."}],"balance_after":3457,"source":{"system":"sec-edgar","filing":"0001209191-20-009834","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120009834/doc4.xml","form_type":"4"}},{"id":3271584,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Common Stock","published_at":"2020-02-14T19:40:17.000Z","date":"2020-02-13","kind":"exercise","acquired":true,"shares":2000,"price":35.6,"value":71200.0,"ownership":{"direct":true},"balance_after":7957,"source":{"system":"sec-edgar","filing":"0001209191-20-009834","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120009834/doc4.xml","form_type":"4"}},{"id":3271583,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Common Stock","published_at":"2020-02-14T19:40:17.000Z","date":"2020-02-13","kind":"exercise","acquired":true,"shares":2500,"price":19.4,"value":48500.0,"ownership":{"direct":true},"balance_after":5957,"source":{"system":"sec-edgar","filing":"0001209191-20-009834","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919120009834/doc4.xml","form_type":"4"}},{"id":3393093,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Performance Restricted Stock Unit","published_at":"2019-10-16T20:18:17.000Z","date":"2019-10-14","kind":"exercise","acquired":false,"shares":6300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"The amount reported in Column 7 of Table II represents the common shares that vested on October 14, 2019. Under the PRSUs, the Reporting Person has a contingent right to receive up to 18,900 additional common shares if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."}],"balance_after":18900,"derivative":{"expiration_date":"2022-01-03","underlying":"Common Stock","underlying_shares":6300},"source":{"system":"sec-edgar","filing":"0001209191-19-053333","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119053333/doc4.xml","form_type":"4"}},{"id":3393092,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Common Stock","published_at":"2019-10-16T20:18:17.000Z","date":"2019-10-14","kind":"tax_withholding","acquired":false,"shares":3091,"price":47.32,"value":146266.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the PRSUs."}],"balance_after":3457,"source":{"system":"sec-edgar","filing":"0001209191-19-053333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119053333/doc4.xml","form_type":"4"}},{"id":3393091,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Common Stock","published_at":"2019-10-16T20:18:17.000Z","date":"2019-10-14","kind":"exercise","acquired":true,"shares":6300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On January 4, 2019, the Reporting Person was granted 12,600 target Performance Restricted Stock Units (\"PRSUs\"). The PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 50%, 100%, or 200% of the target PRSU amount. Such common shares vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019, through January 3, 2022 (the \"Performance Period\") and satisfaction of a subsequent continuing service requirement. On October 14, 2019, 6,300 of the shares subject to the PRSUs vested (50% of the target amount). Up to an additional 18,900 shares remain issuable pursuant to the PRSUs (200% of the target amount, less the 50% already vested) if all currently outstanding Closing Price targets are met during the Performance Period and subsequent continuing service requirements are met."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 62 shares acquired on March 31, 2017, and 62 shares acquired on June 30, 2017, pursuant to the 2009 Arena Employee Stock Purchase Plan."}],"balance_after":6548,"source":{"system":"sec-edgar","filing":"0001209191-19-053333","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119053333/doc4.xml","form_type":"4"}},{"id":3700981,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Employee Performance Restricted Stock Unit","published_at":"2019-01-08T21:00:12.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":12600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Employee Performance Restricted Stock Unit (\"PRSU\") represents a contingent right to receive shares of Arena's common stock, which shares shall vest, if at all, upon the closing price of Arena's common stock (the \"Closing Price\") reaching certain thresholds during the three-year performance period from January 4, 2019 through January 3, 2022 (the \"Performance Period\") and satisfaction of a continuing service requirement."},{"field":"shares","element":"transactionShares","label":"F3","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"The number of shares that may vest is based on the Closing Price during the Performance Period. If, on 5 consecutive or 10 non-consecutive trading days during the Performance Period, the Closing Price equals or exceeds $60, $67.50 or $75, and the reporting person thereafter satisfies a continuing service requirement, the PRSUs are deemed vested at 50%, 100% or 200%, respectively, of the target amount reported in Column 7 (subject, in the event of a change of control, to additional vesting in circumstances where the per share transaction consideration falls in between the dollar values listed above), and the reporting person will receive at or following the time of vesting a number of shares equal to the achieved percentage multiplied by the total number of PRSUs. For the avoidance of doubt, shares may be issued following achievement of each price threshold, and the maximum number of shares that may be issued pursuant to the PRSUs equals 200% of the number of PRSUs reported in Column 5."}],"balance_after":12600,"derivative":{"expiration_date":"2022-01-03","underlying":"Common Stock","underlying_shares":12600},"source":{"system":"sec-edgar","filing":"0001209191-19-002950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119002950/doc4.xml","form_type":"4"}},{"id":3700980,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-01-08T21:00:12.000Z","date":"2019-01-04","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over four years, with 25% of the shares subject to the option vesting on January 4, 2020, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":75000,"derivative":{"exercise_price":40.94,"expiration_date":"2026-01-04","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-19-002950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919119002950/doc4.xml","form_type":"4"}},{"id":4093799,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-01-22T17:28:59.000Z","date":"2018-01-19","kind":"grant","acquired":true,"shares":130000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest over four years, with 25% of the shares subject to the option vesting on January 19, 2019, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":130000,"derivative":{"exercise_price":35.6,"expiration_date":"2025-01-19","underlying":"Common Stock","underlying_shares":130000},"source":{"system":"sec-edgar","filing":"0001209191-18-004771","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919118004771/doc4.xml","form_type":"4"}},{"id":4450574,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-02-14T20:21:54.000Z","date":"2017-02-13","kind":"grant","acquired":true,"shares":1044750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest over four years, with 25% of the shares subject to the option vesting on February 13, 2018, and the remainder of the shares vesting monthly over the following three years in equal installments (except as otherwise necessary to avoid vesting of a fractional share), and are exercisable once vested."}],"balance_after":1044750,"derivative":{"exercise_price":1.46,"expiration_date":"2024-02-13","underlying":"Common Stock","underlying_shares":1044750},"source":{"system":"sec-edgar","filing":"0001209191-17-010903","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117010903/doc4.xml","form_type":"4"}},{"id":4450573,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Common Stock","published_at":"2017-02-14T20:21:54.000Z","date":"2016-12-30","kind":"other","acquired":true,"shares":625,"price":1.21,"value":756.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired pursuant to the 2009 Arena Employee Stock Purchase Plan."}],"balance_after":1250,"source":{"system":"sec-edgar","filing":"0001209191-17-010903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117010903/doc4.xml","form_type":"4"}},{"id":4450572,"issuer":{"id":94856,"kind":"organization","name":"ARENA PHARMACEUTICALS INC"},"owners":[{"id":27193,"kind":"person","name":"Lind Kevin Robert","position":1,"cik":"0001677036","reported_name":"Lind Kevin Robert","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive VP and CFO"}}],"security":"Common Stock","published_at":"2017-02-14T20:21:54.000Z","date":"2016-09-30","kind":"other","acquired":true,"shares":625,"price":1.41,"value":881.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These shares were acquired pursuant to the 2009 Arena Employee Stock Purchase Plan."}],"balance_after":625,"source":{"system":"sec-edgar","filing":"0001209191-17-010903","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1080709/000120919117010903/doc4.xml","form_type":"4"}}]}